These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28771103)

  • 1. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH; Stashwick C; Plesa G; Tanyi JL
    Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
    Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
    O'Hara M; Stashwick C; Haas AR; Tanyi JL
    Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
    Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
    Mayor M; Zeltsman M; McGee E; Adusumilli PS
    Immunotherapy; 2016 May; 8(5):491-4. PubMed ID: 27140404
    [No Abstract]   [Full Text] [Related]  

  • 6. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
    Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Zhao Y; Moon E; Carpenito C; Paulos CM; Liu X; Brennan AL; Chew A; Carroll RG; Scholler J; Levine BL; Albelda SM; June CH
    Cancer Res; 2010 Nov; 70(22):9053-61. PubMed ID: 20926399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T-cell therapy of solid tumors.
    Yong CSM; Dardalhon V; Devaud C; Taylor N; Darcy PK; Kershaw MH
    Immunol Cell Biol; 2017 Apr; 95(4):356-363. PubMed ID: 28003642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
    Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
    Maus MV; Haas AR; Beatty GL; Albelda SM; Levine BL; Liu X; Zhao Y; Kalos M; June CH
    Cancer Immunol Res; 2013 Jul; 1(1):26-31. PubMed ID: 24777247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
    Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
    Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
    Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
    J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
    Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
    Zeltsman M; Dozier J; McGee E; Ngai D; Adusumilli PS
    Transl Res; 2017 Sep; 187():1-10. PubMed ID: 28502785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: A glimpse into the future.
    Wang Y; Zhao G; Xing S; Wang S; Li N
    Pharmacol Res; 2024 Jun; 204():107220. PubMed ID: 38768670
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor-targeting domains for chimeric antigen receptor T cells.
    Bezverbnaya K; Mathews A; Sidhu J; Helsen CW; Bramson JL
    Immunotherapy; 2017 Jan; 9(1):33-46. PubMed ID: 28000526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
    Li K; Lan Y; Wang J; Liu L
    Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    Tanyi JL; Stashwick C; Plesa G; Morgan MA; Porter D; Maus MV; June CH
    J Immunother; 2017 Apr; 40(3):104-107. PubMed ID: 28234665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.